Clinical Outcome Assessments in Pediatric Patients With Ulcerative Colitis and Crohn’s Disease Receiving Biologics: A Retrospective Cohort Study
暂无分享,去创建一个
Nanhua Zhang | W. Crandall | R. Colletti | S. Steiner | Chunyan Liu | K. Benkov | W. Komocsar | T. Hunter | Jennifer L. Dotson
[1] J. Adler,et al. Reduced Systemic Corticosteroid Use among Pediatric Patients With Inflammatory Bowel Disease in a Large Learning Health System , 2021, Journal of pediatric gastroenterology and nutrition.
[2] J. Adler,et al. Factors Associated With Development of Perianal Fistulas in Pediatric Patients With Crohn's Disease. , 2020, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[3] M. Cottone,et al. Effectiveness and safety of biologics in pediatric inflammatory boweldisease: Real-life data from the Sicilian Network. , 2020, Clinics and research in hepatology and gastroenterology.
[4] B. Zikmund‐Fisher,et al. A New Video Aid for Communicating Risk in the Treatment of Pediatric Inflammatory Bowel Disease. , 2019, Journal of pediatric gastroenterology and nutrition.
[5] T. H. Nguyen,et al. The global, regional, and national burden of inflammatory bowel disease in 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017 , 2019, The lancet. Gastroenterology & hepatology.
[6] B. Sands,et al. Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis. , 2019, The New England journal of medicine.
[7] Siddharth Singh,et al. Corticosteroid-Free Remission vs Overall Remission in Clinical Trials of Moderate-Severe Ulcerative Colitis and Crohn's Disease. , 2019, Inflammatory bowel diseases.
[8] W. Treem,et al. Prevalence of Inflammatory Bowel Disease in Pediatric and Adult Populations: Recent Estimates From Large National Databases in the United States, 2007-2016. , 2019, Inflammatory bowel diseases.
[9] S. Ng,et al. Best practices on immunomodulators and biologic agents for ulcerative colitis and Crohn's disease in Asia , 2019, Journal of gastroenterology and hepatology.
[10] J. Hugot,et al. Management of Paediatric Patients With Medically Refractory Crohn’s Disease Using Ustekinumab: A Multi-Centred Cohort Study , 2018, Journal of Crohn's & colitis.
[11] J. Philpott,et al. Challenges in Transitional Care in Inflammatory Bowel Disease: A Review of the Current Literature in Transition Readiness and Outcomes. , 2018, Inflammatory bowel diseases.
[12] R. Enns,et al. Sustained Steroid Free Remission at One Year in Corticosteroid Dependent Ulcerative Colitis Patients on Vedolizumab , 2018, American Journal of Gastroenterology.
[13] A. Griffiths,et al. Management of Paediatric Ulcerative Colitis, Part 2: Acute Severe Colitis—An Evidence-based Consensus Guideline From the European Crohn's and Colitis Organization and the European Society of Paediatric Gastroenterology, Hepatology and Nutrition , 2018, Journal of pediatric gastroenterology and nutrition.
[14] S. Saeed,et al. Inflammatory Bowel Disease in Children and Adolescents. , 2021, Advances in pediatrics.
[15] T. Murdoch,et al. Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target , 2015, The American Journal of Gastroenterology.
[16] J. Hyams,et al. Well-Defined and Reliable Clinical Outcome Assessments for Pediatric Crohn Disease: A Critical Need for Drug Development , 2015, Journal of pediatric gastroenterology and nutrition.
[17] Christopher F. Martin,et al. Evaluation of the patient-reported outcomes measurement information system in a large cohort of patients with inflammatory bowel diseases. , 2014, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[18] Keith Marsolo,et al. Effectiveness of Anti-TNFα for Crohn Disease: Research in a Pediatric Learning Health System , 2014, Pediatrics.
[19] L. Peyrin-Biroulet,et al. Histologic remission: the ultimate therapeutic goal in ulcerative colitis? , 2014, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[20] M. Dubinsky,et al. Balancing and Communicating the Risks and Benefits of Biologics in Pediatric Inflammatory Bowel Disease , 2013, Inflammatory bowel diseases.
[21] R. Bagin,et al. Once-daily budesonide MMX® extended-release tablets induce remission in patients with mild to moderate ulcerative colitis: results from the CORE I study. , 2012, Gastroenterology.
[22] A. Griffiths,et al. Safety and efficacy of adalimumab for moderate to severe Crohn's disease in children. , 2012, Gastroenterology.
[23] P. Margolis,et al. Improved Outcomes in a Quality Improvement Collaborative for Pediatric Inflammatory Bowel Disease , 2012, Pediatrics.
[24] P. Moayyedi,et al. Efficacy of Biological Therapies in Inflammatory Bowel Disease: Systematic Review and Meta-Analysis , 2011, The American Journal of Gastroenterology.
[25] D. Milov,et al. Short pediatric Crohn's disease activity index for quality improvement and observational research , 2009, Inflammatory bowel diseases.
[26] J. Girardet,et al. Natural history of Crohn's disease: Comparison between childhood‐ and adult‐onset disease , 2010, Inflammatory bowel diseases.
[27] M. Silverberg,et al. Severe pediatric ulcerative colitis: a prospective multicenter study of outcomes and predictors of response. , 2010, Gastroenterology.
[28] G. D'Haens. Top-down therapy for IBD: rationale and requisite evidence , 2010, Nature Reviews Gastroenterology &Hepatology.
[29] David C Wilson,et al. Definition of phenotypic characteristics of childhood-onset inflammatory bowel disease. , 2008, Gastroenterology.
[30] A. Griffiths,et al. Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children. , 2007, Gastroenterology.
[31] A. Zinsmeister,et al. A population‐based study of the frequency of corticosteroid resistance and dependence in pediatric patients with Crohn's disease and ulcerative colitis , 2006, Inflammatory bowel diseases.
[32] A. Griffiths,et al. Evaluation of the Pediatric Crohn Disease Activity Index: A Prospective Multicenter Experience , 2005, Journal of pediatric gastroenterology and nutrition.
[33] R. Shamir,et al. A Comparison of Budesonide and Prednisone for the Treatment of Active Pediatric Crohn Disease , 2003, Journal of pediatric gastroenterology and nutrition.
[34] J. R. Landis,et al. The measurement of observer agreement for categorical data. , 1977, Biometrics.